UpdatesGeneral Updates
Zydus Lifesciences' FY26 revenues rose 17% to Rs. 27,150 Cr with 31.2% EBITDA.
Zydus Lifesciences LimitedZYDUSLIFE · Filed with the exchange
US FDA granted Saroglitazar NDA Priority Review, targeting Q4 FY27 launch.
The company declared Re.
1 dividend and approved a Rs. 1,100 Cr share buyback, forecasting high-teen revenue growth for FY27.
No comments yet. Be the first.